60
Participants
Start Date
July 25, 2017
Primary Completion Date
August 18, 2019
Study Completion Date
December 31, 2025
Savolitinib
600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously
Sunitinib
50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
Research Site, Seoul
Research Site, New York
Research Site, Orbassano
Research Site, Goyang-si
Research Site, Milan
Research Site, Incheon
Research Site, Pavia
Research Site, Atlanta
Research Site, Bordeaux
Research Site, Daejeon
Research Site, Nashville
Research Site, Sumy
Research Site, Modena
Research Site, Meldola
Research Site, Dnipro
Research Site, Dnipro
Research Site, Arezzo
Research Site, Iowa City
Research Site, Vandœuvre-lès-Nancy
Research Site, Hwasun-gun
Research Site, Chicago
Research Site, Kharkiv Region
Research Site, Kansas City
Research Site, Odesa
Research Site, Ivano-Frankivsk
Research Site, La Jolla
Research Site, Villejuif
Research Site, Moscow
Research Site, Moscow
Research Site, Moscow
Research Site, Murmansk
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Obninsk
Research Site, Volgograd
Research Site, Nizhny Novgorod
Research Site, Omsk
Research Site, Krasnoyarsk
Research Site, Boston
Research Site, Barretos
Research Site, Curitiba
Research Site, Passo Fundo
Research Site, Pelotas
Research Site, Porto Alegre
Research Site, Porto Alegre
Research Site, Porto Alegre
Research Site, Rio de Janeiro
Research Site, São José do Rio Preto
Research Site, São Paulo
Research Site, São Paulo
Research Site, Roma
Research Site, Moscow
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Kyiv
Research Site, Kyiv
Lead Sponsor
Hutchison Medipharma Limited
INDUSTRY
AstraZeneca
INDUSTRY